2021
The relationship of smoking and unhealthy alcohol use to the HIV care continuum among people with HIV in an integrated health care system
Satre DD, Levine-Hall T, Sterling SA, Young-Wolff KC, Lam JO, Alexeeff S, Hojilla JC, Williams A, Justice AC, Sterne J, Cavassini M, Bryant KJ, Williams EC, Horberg MA, Volberding P, Weisner C, Silverberg MJ. The relationship of smoking and unhealthy alcohol use to the HIV care continuum among people with HIV in an integrated health care system. Drug And Alcohol Dependence 2021, 219: 108481. PMID: 33429295, PMCID: PMC7869693, DOI: 10.1016/j.drugalcdep.2020.108481.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useHIV care continuum outcomesIntegrated health care systemCare continuum outcomesAlcohol useHealth care systemContinuum outcomesCare continuumOdds ratioHigher oddsKaiser Permanente Northern CaliforniaCare systemHIV RNA controlPrimary care screeningHIV care continuumRelationship of smokingAdjusted odds ratioSeparate logistic regression modelsLogistic regression modelsRace/ethnicityHIV careHIV RNASmoking statusMean ageCare screening
2019
HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status
Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D’Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, Re V. HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status. Journal Of The National Cancer Institute 2019, 112: 747-755. PMID: 31687755, PMCID: PMC7357318, DOI: 10.1093/jnci/djz214.Peer-Reviewed Original ResearchConceptsRisk of HCCHigher HIV RNAHCC risk factorsHIV RNAHIV viremiaHepatocellular carcinomaBaseline cirrhosisCirrhosis statusCohort studyRisk factorsCell percentageVeterans Aging Cohort StudyDevelopment of HCCCurrent HIV RNADetectable HIV viremiaHepatitis C coinfectionAging Cohort StudyDiagnosis of cirrhosisLonger durationDetectable HIVLow CD4C coinfectionCurrent CD4Hazard ratioCancer RegistryEmulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals
Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández‐Díaz S, Meyer L, Seng R, Drozd DR, Seage G, Bonnet F, Le Marec F, Moore RD, Reiss P, Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA. Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals. Statistics In Medicine 2019, 38: 2428-2446. PMID: 30883859, PMCID: PMC6499640, DOI: 10.1002/sim.8120.Peer-Reviewed Original ResearchConceptsHIV-positive individualsCopies/First-line treatment regimenAIDS Research NetworkAIDS-free survivalCells/Integrated Clinical SystemsHIV-CAUSAL CollaborationOutcomes of interestRisk difference estimatesDirect effectAntiretroviral therapyHIV RNACD4 thresholdTreatment regimenNew regimenTreatment strategiesHIV researchTarget trialsRegimenTherapyResearch NetworkTrialsSurvivalClinical systemsContributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies
Althoff KN, Gebo KA, Moore RD, Boyd CM, Justice AC, Wong C, Lucas GM, Klein MB, Kitahata MM, Crane H, Silverberg MJ, Gill MJ, Mathews WC, Dubrow R, Horberg MA, Rabkin CS, Klein DB, Re V, Sterling TR, Desir FA, Lichtenstein K, Willig J, Rachlis AR, Kirk GD, Anastos K, Palella FJ, Thorne JE, Eron J, Jacobson LP, Napravnik S, Achenbach C, Mayor AM, Patel P, Buchacz K, Jing Y, Gange SJ, Research and Design N. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. The Lancet HIV 2019, 6: e93-e104. PMID: 30683625, PMCID: PMC6589140, DOI: 10.1016/s2352-3018(18)30295-9.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseEnd-stage renal disease outcomesPopulation attributable fractionRenal disease outcomesTraditional risk factorsElevated total cholesterolLiver diseaseMyocardial infarctionRisk factorsRenal diseaseTotal cholesterolDisease outcomeHIV RNANorth American AIDS Cohort CollaborationDetectable plasma HIV RNALow CD4 cell countsHepatitis B virus infectionEnd-stage renal diseaseClinical AIDS diagnosisDetectable HIV RNAHIV Clinical CohortLow CD4 countCD4 cell countPlasma HIV RNAB virus infection
2018
Brief Report
Yanik EL, Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Horberg MA, Moore RD, Mathews WC, Justice AC, Hessol NA, Mayor AM, Gill MJ, Brooks JT, Sun J, Althoff KN, Engels EA, Silverberg MJ, Dubrow R. Brief Report. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 499-504. PMID: 29771785, PMCID: PMC6037538, DOI: 10.1097/qai.0000000000001719.Peer-Reviewed Original ResearchConceptsMelanoma incidenceAntiretroviral therapyGeneral populationMelanoma riskNorth American AIDS Cohort CollaborationRelationship of immunosuppressionWhite general populationHIV RNA levelsStandardized incidence ratiosCutaneous melanoma incidenceUltraviolet B exposureHigher melanoma incidenceHigh UVB exposureCohort CollaborationSkin surveillanceCD4 countHIV RNAImmune dysfunctionIncidence ratiosCox regressionHIV replicationRisk factorsCalendar periodWhite raceClinical care
2017
Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population
Drozd DR, Kitahata MM, Althoff KN, Zhang J, Gange SJ, Napravnik S, Burkholder GA, Mathews WC, Silverberg MJ, Sterling TR, Heckbert SR, Budoff MJ, Van Rompaey S, Delaney JAC, Wong C, Tong W, Palella FJ, Elion RA, Martin JN, Brooks JT, Jacobson LP, Eron JJ, Justice AC, Freiberg MS, Klein DB, Post WS, Saag MS, Moore RD, Crane HM. Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 75: 568-576. PMID: 28520615, PMCID: PMC5522001, DOI: 10.1097/qai.0000000000001450.Peer-Reviewed Original ResearchConceptsTraditional CVD risk factorsDetectable HIV RNACVD risk factorsIncidence rateRisk factorsCD4 countHIV RNAMyocardial infarctionCardiovascular diseaseNorth American AIDS Cohort CollaborationType 1 myocardial infarctionHIV-specific factorsLow CD4 countSuppressive antiretroviral treatmentIncidence rate ratiosCohort CollaborationIncident MINA-ACCORDAggressive managementAntiretroviral treatmentMultivariable analysisAtherosclerosis RiskMI riskCommunity cohortGeneral population
2016
Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras
Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Re V, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie EE, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert JJ, Mayor A, Thio CL, Cachay ER, Moore R, Research and Design of IeDEA F, Kirk G, Benson C, Bosch R, Boswell S, Mayer K, Grasso C, Hogg R, Harrigan P, Montaner J, Cescon A, Samji H, Brooks J, Buchacz K, Gebo K, Moore R, Moore R, Rodriguez B, Horberg M, Silverberg M, Thorne J, Goedert J, Jacobsonc L, D'Souza G, Klein M, Rourke S, Burchell A, Rachlis A, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Patel P, Brooks J, Saag M, Mugavero M, Willig J, Eron J, Napravnik S, Kitahata M, Crane H, Kim H, Drozd D, Sterling T, Haas D, Bebawy S, Turner M, Justice A, Dubrow R, Fiellin D, Gange S, Anastos K, Moore R, Saag M, Gange S, Kitahata M, Althoff K, McKaig R, Justice A, Freeman A, Moore R, Freeman A, Lent C, Kitahata M, Van Rompaey S, Crane H, Drozd D, Morton L, McReynolds J, Lober W, Gange S, Althoff K, Abraham A, Lau B, Zhang J, Jing J, Golub E, Modur S, Wong C, Hogan B, Tong W, Liu B. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clinical Infectious Diseases 2016, 63: 1160-1167. PMID: 27506682, PMCID: PMC5064164, DOI: 10.1093/cid/ciw531.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseUse of antiretroviralsESLD riskAntiretroviral therapyLiver diseaseNorth American AIDS Cohort CollaborationTime-updated CD4 cell countModern antiretroviral therapy (ART) eraAntiretroviral therapy eraTenofovir-based regimensCD4 cell countModern antiretroviral therapyHuman immunodeficiency virusIncidence rate ratiosRate ratioCohort CollaborationCoinfected PersonsTherapy eraHCV therapyHIV RNAHepatitis BHepatitis statusImmunodeficiency virusC virusAntiretroviral eraWhen to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries
Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, Mugavero MJ, Hernandez-Diaz S, Meyer L, Seng R, Drozd DR, Seage GR, Bonnet F, Dabis F, Moore RR, Reiss P, van Sighem A, Mathews WC, del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Olson A, Justice AC, Tate JP, Bucher HC, Egger M, Touloumi G, Sterne JA, Costagliola D, Saag M, Hernán MA. When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2016, 72: 214-221. PMID: 26895294, PMCID: PMC4866894, DOI: 10.1097/qai.0000000000000956.Peer-Reviewed Original ResearchConceptsCD4 cell countHIV-positive individualsAntiretroviral therapyCell countAIDS-defining illnessAntiretroviral-naive individualsAIDS Research NetworkMortality hazard ratioHIV-positive personsIntegrated Clinical SystemsHIV-CAUSAL CollaborationVirologic outcomesHIV RNAVirologic failureHazard ratioClinical outcomesProspective studyRisk ratioHigh-income countriesEligible individualsMonths strategyMonthsIllnessDeathTherapy
2014
Increased Risk of Radiographic Emphysema in HIV Is Associated With Elevated Soluble CD14 and Nadir CD4
Attia EF, Akgün KM, Wongtrakool C, Goetz MB, Rodriguez-Barradas MC, Rimland D, Brown ST, Hoo G, Kim J, Lee PJ, Schnapp LM, Sharafkhaneh A, Justice AC, Crothers K. Increased Risk of Radiographic Emphysema in HIV Is Associated With Elevated Soluble CD14 and Nadir CD4. CHEST Journal 2014, 146: 1543-1553. PMID: 25080158, PMCID: PMC4251616, DOI: 10.1378/chest.14-0543.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsBiomarkersCD4 AntigensComorbidityConfidence IntervalsCross-Sectional StudiesFemaleHIV InfectionsHumansLipopolysaccharide ReceptorsLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioPrognosisPulmonary EmphysemaRadiographyReference ValuesRisk AssessmentSensitivity and SpecificitySeverity of Illness IndexSex FactorsStatistics, NonparametricConceptsIndependent risk factorSoluble CD14 levelsHIV infectionRadiographic emphysemaEmphysema severityCD14 levelsRisk factorsHIV-Associated Lung Emphysema (EXHALE) studyHigher soluble CD14 levelsNadir CD4 cell countMultivariable logistic regression modelElevated soluble CD14CD4 cell countCells/μLLower lung zonesRisk of HIVCross-sectional analysisLogistic regression modelsNadir CD4HIV RNALung involvementHIV severityD-dimerDiffuse involvementMultivariable analysisHepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.
Lo Re V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Annals Of Internal Medicine 2014, 160: 369-79. PMID: 24723077, PMCID: PMC4254786, DOI: 10.7326/m13-1829.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsAscitesBacterial InfectionsCarcinoma, HepatocellularCoinfectionEsophageal and Gastric VaricesFemaleGastrointestinal HemorrhageHepatitis C, ChronicHIVHIV InfectionsHumansIncidenceLiver NeoplasmsMaleMedication AdherenceMiddle AgedPeritonitisRetrospective StudiesRNA, ViralTreatment OutcomeViral LoadConceptsCo-infected patientsHepatitis C virusHepatic decompensationAntiretroviral-treated patientsCohort studyNonblack raceC virusHepatitis C virus-monoinfected patientsChronic hepatitis C virusHigh rateAntiretroviral therapy eraDetectable HCV RNAIncident hepatic decompensationBaseline hemoglobin levelRetrospective cohort studySpontaneous bacterial peritonitisAdvanced hepatic fibrosisAdvanced liver fibrosisVeterans Health AdministrationDiagnosis of ascitesRate of decompensationTherapy eraHIV RNAVariceal hemorrhageHCV RNA
2013
Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus–Coinfected Veterans
Anderson JP, Tchetgen E, Re V, Tate JP, Williams PL, Seage GR, Horsburgh CR, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Klein MB, Justice AC. Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus–Coinfected Veterans. Clinical Infectious Diseases 2013, 58: 719-727. PMID: 24285848, PMCID: PMC3922212, DOI: 10.1093/cid/cit779.Peer-Reviewed Original ResearchConceptsHepatitis C virusInitiation of ARTAntiretroviral therapyHepatic decompensationHazard ratioVeterans Aging Cohort Study Virtual CohortHIV/HCV-coinfected patientsHuman immunodeficiency virus (HIV) coinfectionEnd-stage liver diseaseHepatic decompensation eventsIncident hepatic decompensationLiver disease outcomesCombination antiretroviral therapyImmunodeficiency virus coinfectionHospital discharge diagnosisSpontaneous bacterial peritonitisCopies/mLMarginal structural modelsART initiationART regimenDecompensation eventsHIV RNAVariceal hemorrhageBacterial peritonitisLiver failureA Study of Financial Incentives to Reduce Plasma HIV RNA Among Patients in Care
Farber S, Tate J, Frank C, Ardito D, Kozal M, Justice AC, Scott Braithwaite R. A Study of Financial Incentives to Reduce Plasma HIV RNA Among Patients in Care. AIDS And Behavior 2013, 17: 2293-2300. PMID: 23404097, PMCID: PMC3742414, DOI: 10.1007/s10461-013-0416-1.Peer-Reviewed Original ResearchConceptsViral load suppressionFeasibility outcomesPatient acceptabilityPatient comprehensionPlasma HIV RNADetectable viral loadViral load testsSingle-site studyEligible patientsHIV careHIV RNAART adherenceViral loadHIV transmissionOwn controlPatientsPatient workflowFinancial incentivesOutcomesCareDownstream costsIncentive sizeBiological outcomesAcceptabilityClinicPhysiologic Frailty and Fragility Fracture in HIV-Infected Male Veterans
Womack JA, Goulet JL, Gibert C, Brandt CA, Skanderson M, Gulanski B, Rimland D, Rodriguez-Barradas MC, Tate J, Yin MT, Justice AC, Team F. Physiologic Frailty and Fragility Fracture in HIV-Infected Male Veterans. Clinical Infectious Diseases 2013, 56: 1498-1504. PMID: 23378285, PMCID: PMC3634308, DOI: 10.1093/cid/cit056.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusVACS Index scoreFragility fracturesPhysiologic frailtyVACS IndexMale veteransInhibitor useFracture riskRisk factorsVeterans Aging Cohort Study (VACS) IndexIndex scoreFragility fracture risk factorsICD-9-CM codesProtease inhibitor useFracture risk factorsMarkers of inflammationBody mass indexUpper arm fracturesAlcohol-related diagnosesCox regression modelFirst fragility fractureCause mortalityHIV RNAHemoglobin levelsMass index
2012
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.
Althoff KN, Buchacz K, Hall HI, Zhang J, Hanna DB, Rebeiro P, Gange SJ, Moore RD, Kitahata MM, Gebo KA, Martin J, Justice AC, Horberg MA, Hogg RS, Sterling TR, Cescon A, Klein MB, Thorne JE, Crane HM, Mugavero MJ, Napravnik S, Kirk GD, Jacobson LP, Brooks JT. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Annals Of Internal Medicine 2012, 157: 325-35. PMID: 22944874, PMCID: PMC3534765, DOI: 10.7326/0003-4819-157-5-201209040-00005.Peer-Reviewed Original ResearchConceptsCD4 cell countCD4 T-lymphocyte cell countMedian CD4 cell countT-lymphocyte cell countAntiretroviral therapy useHIV VLCell countNA-ACCORDHIV RNATherapy useViral loadU.S. National HIV/AIDS StrategyHealth outcomesNational HIV/AIDS StrategyCanadian HIV Trials NetworkHIV/AIDS StrategyActive antiretroviral therapyHIV outpatient clinicAnnual cross-sectional analysesHIV Cohort StudyProportion of participantsNational surveillance systemRelated health outcomesSimilar demographic characteristicsCross-sectional analysis
2011
Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone
Tetrault JM, Tate JP, McGinnis KA, Goulet JL, Sullivan LE, Bryant K, Justice AC, Fiellin DA, Team F. Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone. Alcohol Clinical And Experimental Research 2011, 36: 318-324. PMID: 21797892, PMCID: PMC3221963, DOI: 10.1111/j.1530-0277.2011.01601.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlanine TransaminaseAlcoholismAntiretroviral Therapy, Highly ActiveAspartate AminotransferasesCD4 Lymphocyte CountChemical and Drug Induced Liver InjuryCohort StudiesDatabases, FactualDrug InteractionsDrug-Related Side Effects and Adverse ReactionsFemaleHIV InfectionsHumansLiverLiver Function TestsMaleMiddle AgedNaltrexoneNarcotic AntagonistsOpioid-Related DisordersRNA, ViralVeteransConceptsNaltrexone prescriptionAlanine aminotransferaseOpioid dependenceVeterans Aging Cohort Study Virtual CohortAspartate aminotransferaseImpact of naltrexoneSignificant alanine aminotransferaseLiver enzyme elevationMean CD4 countHIV-infected individualsAST changesHepatic safetyHIV biomarkersOral naltrexoneCD4 countHIV RNAMedian durationEnzyme elevationMedian ageAST levelsNaltrexone useHepatic enzymesAntiretroviral effectivenessHIVPatients
2010
HIV and Aging: Time for a New Paradigm
Justice A. HIV and Aging: Time for a New Paradigm. Current HIV/AIDS Reports 2010, 7: 69-76. PMID: 20425560, DOI: 10.1007/s11904-010-0041-9.Peer-Reviewed Original ResearchConceptsHIV infectionNon-AIDS diseasesCombination antiretroviral therapyPopulation of patientsCause of morbidityComplex chronic diseaseSpectrum of diseaseProlong life expectancyAntiretroviral therapyCD4 countHIV RNAViral suppressionFunctional statusChronic diseasesPatient riskOptimal managementHIVInfectionLife expectancyDiseaseMorbidityMortalityAIDSRiskPatients
2007
Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies
Braithwaite RS, Kozal MJ, Chang CC, Roberts MS, Fultz SL, Goetz MB, Gibert C, Rodriguez-Barradas M, Mole L, Justice AC. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS 2007, 21: 1579-1589. PMID: 17630553, PMCID: PMC3460378, DOI: 10.1097/qad.0b013e3281532b31.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBenzoxazinesCD4 Lymphocyte CountCohort StudiesCyclopropanesDrug Administration ScheduleFemaleHIV InfectionsHIV-1HumansMaleMiddle AgedPatient ComplianceReverse Transcriptase InhibitorsRNA, ViralTreatment OutcomeVeteransViral LoadConceptsPrevious antiretroviral exposureSingle PI regimensCombination ARTImmunological outcomesAntiretroviral exposureHIV RNAPI regimensProtease inhibitorsCombination antiretroviral therapy regimenHIV-RNA viral suppressionTreatment assignmentVeterans Affairs Healthcare SystemEfavirenz-based regimenGreater adherence levelsLog HIV RNAAntiretroviral therapy regimenBaseline clinical characteristicsCD4 cell countCombination antiretroviral therapyPharmacy refill recordsOutcome one yearAntiretroviral prescriptionsAntiretroviral regimensEfavirenz regimensNevirapine regimens